CompletedPhase 3NCT02336230
A Prospective Study of Remestemcel-L, Ex-vivo Cultured Adult Human Mesenchymal Stromal Cells, for the Treatment of Pediatric Participants Who Have Failed to Respond to Steroid Treatment for Acute Graft-Versus-Host Disease (aGVHD)
Studying Graft versus host disease
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Mesoblast, Inc.
- Principal Investigator
- Christopher JamesMesoblast, Inc.
- Intervention
- remestemcel-L(drug)
- Enrollment
- 55 target
- Eligibility
- 17 years · All sexes
- Timeline
- 2015 – 2018
Study locations (20)
- Children's Hospital Los Angeles, Los Angeles, California, United States
- Children's Hospital of Orange County, Orange, California, United States
- University of California at San Francisco, San Francisco, California, United States
- Children's Hospital Colorado Center for Cancer/Blood Disorders, Aurora, Colorado, United States
- Alfred I. DuPont Hospital for Children of the Nemours Foundation, Wilmington, Delaware, United States
- Miami Children's Research Institute, Miami, Florida, United States
- Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, United States
- Children's Hospital of Michigan, Detroit, Michigan, United States
- University of Mississippi Medical Center, Jackson, Mississippi, United States
- Washington University, St Louis, Missouri, United States
- Columbia University Medical Center, New York, New York, United States
- Memorial Sloan Kettering Cancer Center, New York, New York, United States
- Albert Einstein College of Medicine, New York, New York, United States
- Duke University Medical Center, Durham, North Carolina, United States
- Oregon University, Portland, Oregon, United States
- +5 more locations on ClinicalTrials.gov
Collaborators
Quintiles, Inc.
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02336230 on ClinicalTrials.govOther trials for Graft versus host disease
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT07025538Biomarker-Guided Ruxolitinib for the Prevention of Chronic Graft Versus Host Disease After Allogeneic Hematopoietic Cell TransplantationCity of Hope Medical Center
- RECRUITINGPHASE1NCT06996119Emapalumab With Post-Transplant Cyclophosphamide, Tacrolimus and Mycophenolate Mofetil for the Prevention of Graft-versus-Host Disease After Donor Reduced-Intensity Hematopoietic Cell TransplantCity of Hope Medical Center
- RECRUITINGPHASE2NCT07566377Cord Blood Transplantation in Children and Young Adults With Blood CancerMemorial Sloan Kettering Cancer Center
- RECRUITINGPHASE2NCT06926595Allogeneic HSCT With Low-Dose Post-Transplant Cyclophosphamide for GVHD PreventionMilton S. Hershey Medical Center
- RECRUITINGEARLY PHASE1NCT07253259A Clinical Study Evaluating the Safety and Efficacy of GT729 Universal Cell Injection in the Treatment of Refractory or Relapsed Chronic Graft-versus-host Disease (cGVHD)Grit Biotechnology
- RECRUITINGNANCT07166848Electrostimulation Study for Ocular Graft vs. Host DiseaseZhonghui K. Luo, MD, PhD
- RECRUITINGPHASE2NCT07246031BPC2001 for the Prevention of Acute Graft-Versus-Host Disease Following Haploidentical Stem Cell TransplantationBioPhoenix Co., Ltd.
- RECRUITINGNCT07305090Development of a Multi-biomarker Panel for Prognostic Stratification and Treatment Response Prediction in Acute Graft Versus Host Disease of the GutIRCCS Azienda Ospedaliero-Universitaria di Bologna